Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6216]

New nano particles suppress resistance to cancer immunotherapy

New nano particles suppress resistance to cancer immunotherapy

ESMO 2021: New drug shows promise in slowing growth of bowel cancer

ESMO 2021: New drug shows promise in slowing growth of bowel cancer

Innovative ovarian cancer research newly supported by R37 MERIT Award

Innovative ovarian cancer research newly supported by R37 MERIT Award

ESMO 2021: Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage NSCLC

ESMO 2021: Immune checkpoint inhibitor atezolizumab as a potential game-changer in the treatment of early-stage...

ESMO 2021: Tyrosine kinase inhibitor prolongs progression-free survival in rare neuroendocrine tumour

ESMO 2021: Tyrosine kinase inhibitor prolongs progression-free survival in rare neuroendocrine tumour

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer

ESMO 2021: New combination of old drugs improves survival in patients with prostate cancer

ESMO 2021: New combination of old drugs improves survival in patients with prostate cancer

ESMO 2021: First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer

ESMO 2021: First-line CDK 4/6 inhibition shows overall survival benefit for metastatic breast cancer

ESMO 2021: Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma

ESMO 2021: Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma

ESMO 2021: Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

ESMO 2021: Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

More from ecancer